MYMD PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.45 USD | -2.43% |
|
-11.03% | -68.82% |
| Apr. 18 | MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer | CI |
| Apr. 09 | Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data | MT |
Presentation Operator MessageOperator (Operator)Good day, and welcome to Akers Biosciences 202...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Companyâs MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Companyâs second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
| 1st Jan change | Capi. | |
|---|---|---|
| -68.82% | 5.42M | |
| +4.34% | 111B | |
| +11.38% | 105B | |
| -12.38% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.04% | 16.96B | |
| +2.35% | 13.7B | |
| +36.78% | 12.45B |
- Stock Market
- Equities
- MYMD Stock
- News MyMD Pharmaceuticals, Inc.
- Transcript : Akers Biosciences, Inc. - Shareholder/Analyst Call